Recently, according to the global clinical trial database ClinicalTrials,AmgenThe company has officially launched its innovative drugAMG 133The two pivotal Phase III clinical trials — MARITIME-1 and MARITIME-2 — mark an important phase for AMG 133 in Phase III development.

MARITIME-1 is a randomized, double-blind, placebo-controlled study involving 3,501 participants, focusing on evaluatingAMG 133(Low, Medium, High Dose)Efficacy, Safety, and Tolerability in Obese or Overweight Adults Without Type 2 Diabetes. The primary endpoint of the trial is the percentage change in body weight from baseline at Week 72.

Screenshot source: Mesentech Global Drug R&D Database

Meanwhile, MARITIME-2 is a randomized, double-blind, placebo-controlled trial involving 999 obese or overweight adults with type 2 diabetes, also aimed at exploringAMG 133(Low, Medium, High Dose)The key evaluation indicators for its efficacy, safety, and tolerability are consistent with those of MARITIME-1.

AMG 133As a breakthrough first-in-class antibody-peptide conjugate drug independently developed by Amgen, it combines with a fully human monoclonal antibody(Targeting Glucose-Dependent Insulinotropic Polypeptide Receptor GIPR)Compared with two GLP-1 analogs, it achieves an injection frequency of once every 4 weeks. The drug works through a dual mechanism—by inhibiting GIPR and activating the GLP-1 receptor.（GLP-1R）, effectively reducing food intake and regulating metabolism, thereby achieving weight loss and blood sugar reduction.

Screenshot source:Moxie Medicine Global Drug Research and Development Database

Previously in Phase II studies,AMG 133Has demonstrated significant potential for lowering blood sugar and reducing weight. Data shows that after 52 weeks of treatment, obese or overweight adult patients without type 2 diabetes(n=465, baseline average weight 107kg)Average weight loss was 20%, with no plateau in weight reduction observed; for obese or overweight adult patients with type 2 diabetes(n=127, baseline average weight 104kg, baseline average HbA1c level 7.9%), with an average weight loss of 17%, also without encountering a weight-loss plateau, and the average HbA1c level significantly decreased by 2.2%. These positive results provideAMG 133has laid a solid foundation for further development.

END 

Recent Popular Resource Acquisition

Blue Paper on the Current Status and Future Trends of the CGT Industry - 202406

White Paper on the Current Status and Future Trends of the Traditional Chinese Medicine Industry - 202407

2023 Pharmaceutical Enterprise Comprehensive Strength Ranking - 202408

Crossing Borders, Leading Innovation: The Practice of Chinese Pharmaceutical Companies Expanding Overseas - 202408

Five Major Small Molecule Drugs with Patents Soon to Expire: What is the Status of Generic Drugs in China?-202409

Analysis Report on the Current Status of China's Radiopharmaceuticals Market - 202410

Development Prospects of Synthetic Biology Industry and Analysis of Upstream, Midstream, and Downstream Enterprises in China's Synthetic Biology Industry Chain - 202410

China Synthetic Biology Venture Capital Market Analysis Report - 202410

China Diabetes Clinical Diagnosis and Treatment and Drug Multi-Channel Market Data Analysis - 202411

Analysis of Complex Injectable Formulations Based on Dosage Form Modification -- Microspheres Section - 202411

2024 Analysis Report on the Development of the Medical Aesthetics Injection Materials Market - 20241213

National Drug Centralized Procurement Tracking Report - Review and Outlook of the First 9 Batches - 202411

More RecentlyMoxie ConsultingPopular report, scan the QR code below to claim

Contact us to experience more professional services from摩熵医药.
MeetingDiscussion CombineWork	GardenDistrict TakeMission	Database Consultation	Customization Service	Media Cooperation

???ClickImage Above, you can start the Mosan Chemistry data query

ClickReadRead the Original Text, apply for a free trial of Mosu Pharmaceuticals Enterprise Edition!